AtaiBeckley Sets September 8 Vote on $2.8B Eli Lilly Acquisition at $6.75/Share Plus CVRs
ATAI has more than doubled off its 52-week low of $3.265.
Summary
AtaiBeckley filed its definitive proxy for the September 8 vote on Eli Lilly's acquisition, offering $6.75/share cash plus up to $2.50/share in CVRs. The board recommends approval, and key shareholders have committed their votes.
Key Events · M&A and Partnerships · ATAI
-
Definitive Proxy Filed, Vote Set for Sept 8
The definitive proxy statement sets the special meeting for September 8, 2026, with a record date of August 7, 2026. Stockholders will vote on the merger agreement with Eli Lilly.
-
Merger Consideration: $6.75 Cash + CVRs
Each share will receive $6.75 in cash plus one CVR worth up to $2.50 upon achievement of clinical/regulatory milestones for BPL-003 and VLS-01. The upfront cash represents a ~40% premium to the 30-day VWAP before announcement.
-
Board Unanimously Recommends Approval
The AtaiBeckley board unanimously determined the merger is fair and in the best interests of stockholders, citing the premium, certainty of value, and Lilly's resources to advance the pipeline.
-
Key Shareholders Committed to Vote in Favor
Directors, executive officers, and Apeiron Investment Group (holding ~15.4% of shares) have entered voting agreements to support the merger, significantly de-risking the approval.
Analysis · ATAI · Life Sciences
AtaiBeckley's definitive proxy statement locks in the September 8, 2026 special meeting for shareholders to vote on Eli Lilly's $2.8 billion acquisition. The deal offers $6.75 per share in cash plus up to $2.50 per share in contingent value rights tied to clinical and regulatory milestones for its depression therapies. The board unanimously recommends approval, and the largest shareholders, holding over 15% of the stock, have already agreed to vote in favor. The merger has cleared German antitrust review and is progressing through other regulatory approvals. If approved, AtaiBeckley stockholders will receive immediate cash and retain upside exposure to the pipeline's success through the CVRs, while the company gains Lilly's resources to advance its mental health treatments.
At the time of this filing, ATAI was trading at $7.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.7B. The 52-week trading range was $3.27 to $7.25. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.